Nonsteroidal anti-inflammatory drug (NSAID) use contributes substantially to the increased risk of cardiovascular disease among patients with osteoarthritis, say researchers writing in Arthritis & Rheumatology last month.
A proof of concept clinical trial for riociguat (Adempas, Bayer) for patients with systemic sclerosis indicates that longer treatment periods may be necessary to heal digital ulcers. In this trial, the treatment wasn't effective in reducing the number of digital ulcers.
In patients with rheumatoid arthritis, methotrexate adherence is suboptimal and associated with certain demographics, medication experience, and beliefs about medicines, say researchers writing in ACR Open Rheumatology this month.
Triple therapy and methotrexate‐based biologic disease‐modifying antirheumatic drug (DMARD) combinations were superior to methotrexate alone for both American College of Rheumatology (ACR50) response and remission in patients with rheumatoid arthritis, say researchers writing in Arthritis Research & Therapy last month.
Aryeh M. Abeles, M.D., talks with Rheumatology Network about the FDA's black box label for febuxostat, a gout treatment which, according to the results of one clinical trial, was shown to be associated with an increased risk of mortality. In this Q&A, Dr. Abeles, says the decision was based on flawed data.
Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month